A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis
Novartis
Vir Biotechnology, Inc.
Merck Sharp & Dohme LLC
MacroGenics
Merck Sharp & Dohme LLC
Janssen Research & Development, LLC
Aragon Pharmaceuticals, Inc.
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Wake Forest University Health Sciences
Celcuity Inc
Janssen Research & Development, LLC
T.O.A.D. Oncology SA
Pfizer
Northwestern University
MacroGenics
Clarity Pharmaceuticals Ltd
MacroGenics
Bristol-Myers Squibb
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University